Capital AllocationThe company is focusing on capital recycling with the potential sale of $1 billion of outpatient medical assets to be reinvested into new outpatient developments, distressed lab properties, or share repurchases.
Financial PerformanceCore FFO exceeded consensus expectations and guidance was reiterated, benefiting from better general and administrative and interest costs.
Leasing ActivityThe life science leasing pipeline is building, indicating increased activity in that sector.